Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of “Moderate Buy” by Brokerages

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has earned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $36.20.

Several analysts recently commented on the company. The Goldman Sachs Group raised their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. Citigroup increased their price target on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, November 19th. Scotiabank decreased their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Finally, StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd.

Syndax Pharmaceuticals Price Performance

SNDX opened at $16.38 on Friday. Syndax Pharmaceuticals has a 12 month low of $12.06 and a 12 month high of $25.34. The stock has a market cap of $1.40 billion, a P/E ratio of -4.51 and a beta of 0.90. The stock’s 50 day moving average price is $13.97 and its 200 day moving average price is $16.95.

Insider Transactions at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,777 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the sale, the chief financial officer now directly owns 90,746 shares of the company’s stock, valued at $1,406,563. This trade represents a 4.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares of the company’s stock, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,683 shares of company stock valued at $336,087 in the last three months. 4.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SNDX. Inspire Investing LLC boosted its position in shares of Syndax Pharmaceuticals by 23.2% in the third quarter. Inspire Investing LLC now owns 21,308 shares of the company’s stock worth $410,000 after buying an additional 4,018 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Syndax Pharmaceuticals by 8.6% in the third quarter. Assenagon Asset Management S.A. now owns 466,028 shares of the company’s stock worth $8,971,000 after buying an additional 37,079 shares during the period. Values First Advisors Inc. acquired a new stake in shares of Syndax Pharmaceuticals in the third quarter worth $30,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after buying an additional 541 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,367 shares of the company’s stock worth $315,000 after buying an additional 6,383 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).